U.S. Food and Drug Administration at PepTalk 2027

Jan 18–21, 2027 Carlsbad, CA ~1k attendees Website

U.S. Food and Drug Administration brings 3 presentations to PepTalk 2027 in Carlsbad. Its sessions center on the regulation of therapeutic peptides. Topics include clearer ways to assess and reduce immunogenicity risk in peptide products, and how evidence generation can build regulatory certainty for new technologies.

Organization	PepTalk 2027 Attendance
U.S. Food and Drug Administration Silver Spring, MD
fda.gov Gov/NGO US agency that regulates drugs, biologics and medical devices; its Center for Drug Evaluation and Research reviews new drug applications.	Talk Wed Jan 20 3:30pm–4:00pm Therapeutic Peptide Products: Toward Greater Regulatory Clarity in the Assessment and Mitigation of Immunogenicity Risks Peptide Therapeutics: Emerging Modalities & Development Panel Wed Jan 20 5:40pm–6:10pm Stick to the Science—How Evidence Generation Can Build upon Technology Enthusiasm to Advance Both Regulatory Certainty and Market Momentum Peptide Therapeutics: Emerging Modalities & Development · with Novartis, U.S. Pharmacopeia, ELIQUENT Life Sciences Chair Thu Jan 21 1:35pm–1:40pm Chairperson's Remarks Peptide Therapeutics: Emerging Modalities & Development

Organization

PepTalk 2027 Attendance

U.S. Food and Drug Administration

Silver Spring, MD

fda.gov

Gov/NGO

US agency that regulates drugs, biologics and medical devices; its Center for Drug Evaluation and Research reviews new drug applications.

Talk

Wed Jan 20
3:30pm–4:00pm

Therapeutic Peptide Products: Toward Greater Regulatory Clarity in the Assessment and Mitigation of Immunogenicity Risks

Peptide Therapeutics: Emerging Modalities & Development

Panel